Share Price, page-2402

Hi EagleO

No, I don’t have an opinion on what the sp might get to on FDA approval other than that, with an already expected chance of approval of 90%, I wouldn’t expect to see a doubling in sp.

Re potential takeover, I absolutely wouldn't like to see that happen at this point. Too many near-term value inflection points we should benefit from first.

But once (a) trofinetide ROW rights have been licensed (b) FDA approval has been received (which I believe will happen) and (c) Phase 2 results are in for NNZ-2591, it’s something I would give consideraton to.

Waiting for Phase 2 results in NNZ-2591 obviously comes with risk but it’s a risk I’m willing to take, given the size of the potential rewards. If NNZ-2591 Phase 2 trials are successful, there should be a significant jump in company valuation based not only on the probability of approval rising from 25% to 60% , but also increased weight put on the potential for NNZ-2591 to succeed in a broader range of indications.

That said, I'm aware that there are lots of different views on this topic and I realistically accept that my opinion of “when” and “how much” will count for nought when these matters finally play out.